Procaps Group 

Sofgen Pharma S.A., through its various subsidiaries, is engaged in the development, manufacturing, and commercialization of pharmaceutical products across South America, Central America, North America, and Europe. The company’s operations are segmented into five distinct divisions: NextGel, Procaps Colombia, Central America North (CAN), Central America South and North Andes (CASAND), and Diabetrics. The firm specializes in formulating, producing, and selling branded prescription medications for a wide range of therapeutic conditions. These include feminine health, pain management, dermatological issues, digestive disorders, growth and development, cardiovascular diseases, vision care, central nervous system ailments, and respiratory illnesses. Sofgen Pharma also supplies pharmaceuticals for hospital use, such as blood clot treatments, immunosuppressants, oncology drugs, and analgesics. Additionally, its hospital-grade offerings encompass medical devices like personal protective equipment (PPE), various types of syringes (including double-chamber designs), injection vials, ampoules, sterilized powder products, sterile droppers, and lyophilized solid vials. Furthermore, the company boasts a robust portfolio of over-the-counter (OTC) consumer healthcare products, spanning approximately eight therapeutic categories. These include solutions for gastrointestinal issues, skincare, cough and cold symptoms, pain relief, and urological health. Its extensive range also features vitamins, minerals, and dietary supplements, as well as pharmaceuticals addressing diverse medical needs across categories such as antibiotics, anti-infectives, antiparasitics, cardiovascular agents, women's health, cutaneous antimycotics, hormonal treatments, metabolic and endocrine system drugs, nervous system medications, ophthalmic preparations, osteoarticular remedies, and respiratory aids. Beyond these product lines, Sofgen Pharma delivers comprehensive diabetes care and chronic disease management solutions. This includes blood glucose monitoring devices, telemonitoring services, oral antidiabetic medications, cosmeceuticals, and insulin delivery systems. The company also extends its expertise through contract development and manufacturing (CDMO) services, particularly in soft gelatin capsule and gummy technologies, under the brand names Softigel, Sofgen, Softcaps, and Funtrition. Established in 1977 and headquartered in Luxembourg, Luxembourg, Sofgen Pharma S.A. was previously known as Procaps Group S.A.